Synergy's Trulance under FDA review for IBS-C

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said FDA has accepted for review its sNDA for Trulance plecanatide to treat irritable bowel syndrome with constipation. Its PDUFA date is Jan. 24, 2018.

FDA approved Trulance in January to treat chronic idiopathic constipation (CIC). Synergy launched the drug in March (see BioCentury Extra, Jan. 19)...